Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAF + Tamoxifen vs Tamoxifen Alone in Postmenopausal Breast Cancer
NCT00929591Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- May 1989
- Primary completion
- Aug 2005
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, doxorubicin and fluorouracil in breast cancer (3 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Disease-Free Survival at 8 years, Overall Survival at 8 years and 1 more. Started May 1989; status: completed.
02
Drugs
cyclophosphamidedoxorubicinfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00929591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00929591.